{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"220.01","value":"101.49"},{"groupId":"OG001","spread":"394.91","value":"120.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.65","value":"41.45"},{"groupId":"OG001","spread":"128.63","value":"90.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.85","value":"7.52"},{"groupId":"OG001","spread":"23.43","value":"14.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.91","value":"0.78"},{"groupId":"OG001","spread":"0.51","value":"0.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.89","value":"3.49"},{"groupId":"OG001","spread":"1.90","value":"0.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.65","value":"1.00"},{"groupId":"OG001","spread":"0.43","value":"0.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"0.47"},{"groupId":"OG001","spread":"0.77","value":"0.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.84","value":"0.36"},{"groupId":"OG001","spread":"2.09","value":"0.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEAN","populationDescription":"Participants in the Safety Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18 and Month 24","title":"Levels of Anti-CD19 CAR T Cells in Blood","type":"SECONDARY","unitOfMeasure":"cells/μL"}